Week of May 10th, 2021 | Vol. 10, Issue 20
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory
INDUSTRY M&A SNAPSHOT

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in Canada

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Bourne Partners (“Bourne”), a leading financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors announced today the appointment of Paul Campanelli, former CEO of Endo International plc as a senior advisor to the firm.

“Paul is a long-time friend and industry colleague of our firm. He brings a great deal of knowledge and experience that will be invaluable to the continued growth and success of our business,” said Banks Bourne, Founder and CEO of Bourne Partners. “Paul’s contributions will help us as we continue to work together to carry out our company’s growth initiatives that include strategic acquisitions with Bourne Partners Strategic Capital, expanding our M&A advisory business and pipeline, and broadening the variety of services that we provide. We are looking forward to working together to ensure that the business continues to prosper.”

RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
17 transactions totaling $1,150 million
Supplies, Equipment & Services
26 transactions totaling $133 million
Healthcare IT & Managed Care
12 transactions totaling $1,123 million
Healthcare Facilities & Distributors
7 transactions totaling $1,038 million
Pharma & Biotech
31 transactions totaling $1,312 million
Supplies, Equipment & Services
24 transactions totaling $798 million
Healthcare IT & Managed Care
19 transactions totaling $780 million
Healthcare Facilities & Distributors
3 transactions totaling $60 million
Pharma & Biotech
23 transactions totaling $1,628 million
Supplies, Equipment & Services
11 transactions totaling $287 million
Healthcare IT & Managed Care
2 transactions totaling $253 million
Healthcare Facilities & Distributors
0 transactions
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
May 7, 2021 - Contract Pharma
Catalent has acquired Promethera Biosciences’ cell therapy manufacturing subsidiary Hepatic Cell Therapy Support—the fourth company to join Catalent’s swiftly growing cell and gene therapy campus in Gosselies, Belgium. As part of the deal, Catalent will get its hands on HCTS’ 32,400-square-foot plant there, located right alongside the Delphi Genetics facility Catalent picked up earlier this year.

May 6, 2021 - Fierce Pharma
Catalent has acquired Promethera Biosciences’ cell therapy manufacturing subsidiary Hepatic Cell Therapy Support—the fourth company to join Catalent’s swiftly growing cell and gene therapy campus in Gosselies, Belgium. As part of the deal, Catalent will get its hands on HCTS’ 32,400-square-foot plant there, located right alongside the Delphi Genetics facility Catalent picked up earlier this year.

May 5, 2021 - Fierce Healthcare
R1, a publicly-traded company, intends to fund the transaction with a combination of cash from its balance sheet and debt. The transaction provides a tax benefit valued at approximately $40 million, equating to an effective purchase price of approximately $260 million, the company said in a press release issued Tuesday.

May 5, 2021 - Contract Pharma
Contract Pharma spoke with GlobalData’s Peter Shapiro, senior director of drugs and business fundamentals, about the trends he is seeing in the contract services space in the U.S., Europe and Asia. Shapiro discusses how the many recent large COVID contracts have benefited the industry and looks ahead at what the implications might be over the next few years. He explores growth areas like cell and gene therapies, mRNA and vaccines, as well as geopolitical factors and how development capacity constraints are helping drive increased venture capital (VC) interest.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.